0001193125-26-197154
SEC filingRevenue growth from Revuforj and Niktimvo drove a 224% increase, while net loss narrowed 50% as operating expenses declined.
Operating income improved to a loss of $34.2 million from a loss of $83.8 million in the prior year, a 59.2% improvement. The operating margin was -52.7%, reflecting the company's continued investment in commercialization and R&D. The improvement in operating income was driven by revenue growth, partially offset by costs associated with expanding commercial operations and ongoing development activities. Cost of goods sold for Revuforj may not include full manufacturing costs until pre-launch inventory is depleted.
The company continues to focus on commercializing Revuforj and advancing its pipeline. Cost-sharing amounts received from partners are recorded as reductions to R&D expense. Interest expense primarily relates to capital leases. The company expects to continue investing in development and commercialization activities to support growth.